Current status of transcatheter aortic valve replacement

Area of Science:

• Cardiology
• Interventional Cardiology
• Cardiac Surgery

Background:

• Surgical aortic valve replacement (SAVR) has historically been the primary treatment for severe aortic stenosis.
• Transcatheter aortic valve replacement (TAVR) is emerging as a leading alternative, especially for non-surgical candidates.
• TAVR offers potential benefits in reducing morbidity and mortality for select high-risk operable patients.

Purpose of the Study:

• To review the current role and evolving landscape of TAVR in managing severe aortic stenosis.
• To discuss the advantages and limitations of TAVR compared to SAVR.
• To highlight the importance of ongoing research and patient selection in TAVR therapy.

Main Methods:

• Review of current literature and clinical trial data on TAVR and SAVR.
• Analysis of patient outcomes, including morbidity, mortality, and procedural complications.
• Discussion of technological advancements and future directions in transcatheter valve therapy.

Main Results:

• TAVR is the standard of care for symptomatic patients with severe aortic stenosis who are not candidates for SAVR.
• TAVR may be a preferred option over SAVR in carefully selected high-risk operable patients.
• While TAVR outcomes are improving, concerns regarding vascular injury, stroke, paravalvular regurgitation, and valve durability persist.

Conclusions:

• TAVR is becoming a more appealing option for a broader patient population due to ongoing refinements in systems, techniques, and patient selection.
• Randomized trials and surveillance are crucial for the rigorous clinical evaluation of minimally invasive structural heart disease therapies.
• The field is entering a new era of evidence-based assessment for TAVR and other transcatheter interventions.